

(<http://www.aphanet.org>)

[Home](#) > Treatment of pancreatic tumors

---

**Generic Name:**

Everolimus

**Trade Name:**

Afinitor

**Company:**

Novartis

**Notes:**

Approval was based on data from a randomized, double-blind, multicenter trial that compared use of [everolimus](#) 10 mg once daily plus best supportive care (n = 207) versus placebo plus best supportive care (n = 203) in patients with disease progression within the previous 12 months. Treatment with everolimus resulted in a statistically significant improvement in investigator-determined progression-free survival compared with placebo (median 11.0 vs. 4.6 mo).

**Medication Monitor Categories:**

[Supplemental Approvals](#)

**Use:**

Treatment of patients with progressive neuroendocrine tumors located in the pancreas that are unresectable, locally advanced, or metastatic

---

**Source URL:** <http://www.aphanet.org/supplemental-approvals/treatment-pancreatic-tumors>